Junction: Multiple Sclerosis

First US Patient Dosed With Investigational Stem Cell Therapy IMS001 for MS

The first US patient has been dosed with an investigational stem cell therapy called IMS001, for multiple sclerosis (MS). ImStem Biotechnology, the therapy’s developer, announced in a press release that the first patient had been dosed in their phase 1 clinical trial (NCT04956744). IMS001’s safety, tolerability, and exploratory effectiveness are being investigated for patients with…

Lower Socioeconomic Status May Lead to Faster Retinal Neurodegeneration in MS

Researchers discovered that poorer socioeconomic status is associated with faster retinal neurodegeneration in patients with multiple sclerosis (MS), according to a study published in Brain. In epidemiological studies, scientists are increasingly interested in whether socioeconomic status plays a role in affecting the course of a disease. “Socioeconomic status is a combination of financial, educational and occupational…

MS Treatment With Ocrelizumab Led to High NEDA Rates

Ocrelizumab (Ocrevus®) treatment led to high rates of “no evidence of disease activity” (NEDA) in patients with multiple sclerosis (MS), found a new study published in the European Journal of Neurology. These are findings from a prospective, multicenter, open-label, phase 3b clinical trial called CASTING that aimed to assess the safety and efficacy of ocrelizumab…

Newly Developed Multiplex Network Could Improve Rare Disease Research

Researchers in Austria developed a multiplex network by mapping genes and their interactions on multiple levels, which can help better identify genetic defects and study their consequences.  To build the network, the team led by Jörg Menche, PhD, adjunct principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences…

Next post in MS News Briefs